"Alkylating Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
| Descriptor ID |
D000477
|
| MeSH Number(s) |
D27.505.519.124 D27.888.569.035
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Alkylating Agents".
Below are MeSH descriptors whose meaning is more specific than "Alkylating Agents".
This graph shows the total number of publications written about "Alkylating Agents" by people in this website by year, and whether "Alkylating Agents" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 2 | 1 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 1 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 3 | 4 |
| 2006 | 0 | 2 | 2 |
| 2007 | 3 | 1 | 4 |
| 2008 | 3 | 2 | 5 |
| 2009 | 2 | 0 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 3 | 4 |
| 2013 | 3 | 2 | 5 |
| 2014 | 3 | 2 | 5 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 3 | 4 |
| 2017 | 0 | 2 | 2 |
| 2018 | 3 | 3 | 6 |
| 2019 | 0 | 2 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
Below are the most recent publications written about "Alkylating Agents" by people in Profiles.
-
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study. Eur J Haematol. 2024 Mar; 112(3):402-411.
-
Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality. Ophthalmology. 2023 Dec; 130(12):1258-1268.
-
Response to the feasibility of Kreher et al's "Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: methotrexate, alkylating agents, biologics, and small molecule inhibitors". J Am Acad Dermatol. 2023 10; 89(4):e181-e185.
-
Postoperative Complications in the Primary Tube Versus Trabeculectomy Study During 5 Years of Follow-up. Ophthalmology. 2022 12; 129(12):1357-1367.
-
The UVSSA protein is part of a genome integrity homeostasis network with links to transcription-coupled DNA repair and ATM signaling. Proc Natl Acad Sci U S A. 2022 03 15; 119(11):e2116254119.
-
Repeated Low-Dose Acrolein Triggers Irreversible Lamina Propria Edema in Urinary Bladder, Transient Voiding Behavior and Widening of Eyes to Mechanical Stimuli. Cells. 2021 12 09; 10(12).
-
Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma. Hepatology. 2021 10; 74(4):1932-1951.
-
A Comparison of Trabeculectomy Surgery Outcomes With Mitomycin-C Applied by Intra-Tenon Injection Versus Sponge. Am J Ophthalmol. 2020 08; 216:243-256.
-
Hypotony Keratopathy Following Trabeculectomy. J Glaucoma. 2020 Feb; 29(2):77-80.
-
The DNA repair enzyme MUTYH potentiates cytotoxicity of the alkylating agent MNNG by interacting with abasic sites. J Biol Chem. 2020 03 13; 295(11):3692-3707.